Karyopharm Therapeutics
Ms. DiPaolo was appointed as Executive Vice President, Chief Human Resources Officer, and Head of People & Culture in September of 2022. She brings more than 20 years of pharmaceutical and biotech experience to her new role.
Most recently, Ms. DiPaolo served as Senior Vice President, Human Resources, at Ipsen where she led the Human Resources function for the North America business as well as global R&D and Business Development where she successfully led broad organization transformation to scale the business. During her tenure, she was also responsible for building and leading compensation and benefits, talent management, and talent acquisition globally. Previously, Ms. DiPaolo spent 8 years at Biogen in several leadership roles, and in her last role served as Vice President, Global Therapeutic Operations, Global Medical, and Executive search. Earlier in her career, she led North America Human Resources at Smiths Medical, and prior to that, she spent a decade at Novartis in various leadership roles both in the U.S. and globally.
Ms. DiPaolo holds a Bachelor of Arts degree from Montclair State University and a Master of Human Resource Management from Rutgers University.
This person is not in any offices
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).